Ten years of experience in patients with resected pancreatic tumors: Real-world data in a public institution in Peru.

• DOI: 10.1200/jco.2023.41.4_suppl.686
• Publication Date: 2023-01-24T21:05:07Z
• Authors: Jackeline Macetas; Heberth Daniel Va...; Eder Christian Ve...; Mariana Serrano; Cristian Pacheco; Victor Castro Oliden; Raul Mantilla; Paola Catherine M...
• Keywords: Serous Cystadenoma

686 Background: In Peru, the incidence of pancreatic tumors is 3.59 per 100,000 inhabitants, being ninth cause death. The standard treatment in world surgery, achieved 13% patients, with overall survival (OS) and disease-free (PFS) at 5 years 10% 34%, respectively. our study, different subtypes that were resected by their clinical/pathological characteristics, OS PFS evaluated. Methods: A retrospective review was carried out, patients older than 18 years, diagnosed treated first intention during 2010 - 2019. 36.9% adenocarcinoma (AD), 36.2% solid pseudopapillary neoplasm, 20.6% serous cystadenoma, 3.5% intraductal papillary mucinous 2.1% cystic 0.7% acinar cell carcinoma. Kaplan Meir method used to estimate PFS, log-rank test differentiate between estimated curves. Results: 141 tumors; 73.8% without comorbidities Diabetes Mellitus. Jaundice debut present 22.7%, whom 60% AD; 23.7% jaundice vs 69.9% jaundice, 55.3% located head pancreas, 78.8% an 50.1% 67.3% not pancreas. According staging (S), 14.2% S I, 43.3% IIA, IIB, 22% III; 100% AD IIB-III 8.9% non-AD, III 16.2% IIB 39.3%. 57.7% 73.5%, For AD, 22.9% 36.9%, Conclusions: study suggests debut, IIB-III, are worse prognostic factor tumors, especially AD. And presents greater compared literature, although more evidence still required due type study.